Positron, Jubilant ink cardiac PET deal

Jubilant DraxImage, a Jubilant Life Sciences company, and Positron executed a letter of intent related to Positron's supply of active pharmaceutical ingredient grade strontium-82 (Sr-82) for Jubilant's Sr-82/rubidium-82 (Rb-82) generator; the co-promotion of Jubilant's Sr-82/Rb-82 generators to end-users (upon FDA clearance); and Positron's lifecycle management for expired Jubilant's Sr-82/Rb-82 generators.

The alliance between Jubilant of Kirkland, Québec, and Positron of Fishers, Ind., will seek to increase the supply of radioisotopes and radiopharmaceuticals. In the agreement, Positron will seek to secure a generator supply for future sales of cardiac PET scanners and a customer for Sr-82, while Jubilant will seek to secure a "reliable supply" of Sr-82, a vendor for expired generators management, and a strategic partner with a customer base of cardiac PET scanners installed and serviced, according to a joint release.

Jubilant and Positron expect to complete a definitive agreement within three months.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.